title: Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT.
abstract: Fifteen patients fulfilling DSM-IV criteria for major depression were investigated with the specific dopamine D2 receptor antagonist [123I]iodobenzamide (IBZM). Two single photon emission computed tomography (SPECT) examinations were performed before and after 6 weeks of treatment with a selective serotonin re-uptake inhibitor (SSRI). Striatal D2 receptor binding was calculated and normalized to the cerebellum. In a non-psychiatric control group (n = 17), which was investigated once with [123I]IBZM and SPECT, striatal IBZM binding decreased significantly with age (0.092 per decade). The age-dependent correlation was lower in subjects with major depression and did not reach statistical significance. There was no significant difference in mean IBZM binding between depressives and control subjects. Age-corrected baseline IBZM binding in the striatum was significantly lower in treatment responders than in depressed non-responders and control subjects. Furthermore, in the depressive group there was a significant linear correlation between treatment response and change of D2 receptor binding during treatment in the basal ganglia. IBZM binding increased in treatment responders and decreased in non-responders. In accordance with animal studies, the results suggest an association between changes in the dopaminergic system and treatment response in major depression.
authors.affiliation: Department of Psychiatry, University of Düsseldorf, Germany. kn34010@mail.lvr.de
authors.forename: A
authors.initials: A
authors.lastname: Klimke
authors.forename: R
authors.initials: R
authors.lastname: Larisch
authors.forename: A
authors.initials: A
authors.lastname: Janz
authors.forename: H
authors.initials: H
authors.lastname: Vosberg
authors.forename: H W
authors.initials: HW
authors.lastname: Müller-Gärtner
authors.forename: W
authors.initials: W
authors.lastname: Gaebel
mesh_terms: D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001549:Benzamides; D001569:Benzodiazepines; D016022:Case-Control Studies; D003287:Contrast Media; D003342:Corpus Striatum / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000378:metabolism; D003865:Major Depressive Disorder / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use; D006801:Humans; D008297:Male; D017374:Paroxetine / Q000627:therapeutic use; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2 / Q000187:drug effects* / Q000378:metabolism*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D014151:Anti-Anxiety Agents; D001549:Benzamides; D001569:Benzodiazepines; D003287:Contrast Media; D005473:Fluoxetine; D017374:Paroxetine; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; D017367:Selective Serotonin Reuptake Inhibitors; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide